Difference between revisions of "Zanubrutinib (Brukinsa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 24: | Line 24: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
Revision as of 23:19, 28 February 2020
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 11/14/2019: Granted accelerated approval for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Also known as
- Code name: BGB-3111
- Brand name: Brukinsa